Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 1/2024

27-11-2023 | Atrial Fibrillation | Letter to the Editor

Comment on “Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients”

Author: Shih-Wei Lai

Published in: Cardiovascular Drugs and Therapy | Issue 1/2024

Login to get access

Excerpt

A population-based cohort study conducted by Dr. Lee et al. showed that there was a lower risk of cardiovascular-related diseases and mortality among persons with type 2 diabetes mellitus (T2DM) who took sodium-glucose cotransporter 2 inhibitors (SGLT2-I) compared with those using dipeptidyl peptidase-4 inhibitors (DPP4-I) [1]. The relative risk reduction is marked in all aspects, but one point that was not mentioned in Lee et al.’s study is worth discussing. …
Literature
1.
Lee S, Zhou J, Leung KSK, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther. 2023;37(3):561–9.CrossRefPubMed
2.
Barratt A, Wyer PC, Hatala R, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ. 2004;171(4):353–8.CrossRefPubMedPubMedCentral
Metadata
Title
Comment on “Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients”
Author
Shih-Wei Lai
Publication date
27-11-2023
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 1/2024
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-023-07527-z

Other articles of this Issue 1/2024

Cardiovascular Drugs and Therapy 1/2024 Go to the issue

Letter to the Editor

Winding Down the Storm: Could Empagliflozin’s Ion-Dependent Mechanisms Tackle the Ventricular Arrhythmia Burden in Chronic Chagas Cardiomyopathy?

Letter to the Editor

The Effect of Colchicine in Acute Myocardial Infarction

Invited Editorial

Dapagliflozin for Atrial Fibrillation

Original Article

Effect of Clinical and Genetic Factors on the Development of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG) in Egyptian Patients Receiving Beta-Blockers

Short Communication

Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a)

Review Article

Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic Review